MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$18,986,376
Net Income
-$6,086,522
Net Profit Margin
-32.06%
EPS
-$0.1
Unit: Dollar
Revenue Breakdown
Greece
Uk
Albania
Cyprus
Revenue Breakdown
Wholesale
Pharmamanufacturing
Nutraceuticals And Pharmaceutica...
Other
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
18,986,376
17,927,892
19,703,160
17,110,425
Cost of goods sold
17,474,714
16,546,721
17,623,816
14,507,807
Gross profit
1,511,662
1,381,171
2,079,344
2,602,618
General and administrative expenses
2,066,053
1,800,162
10,609,632
2,040,341
Salaries and wages
1,855,257
1,397,657
1,949,866
1,919,950
Sales and marketing expenses
98,226
19,352
35,585
64,794
Research and development costs
68,552
0
410,760
18,337
Impairment charges
-
-
162,785
-
Depreciation and amortization expense
349,181
348,179
317,141
377,911
Total operating expenses
4,437,269
3,565,350
13,485,769
4,421,333
Loss from operations
-2,925,607
-2,184,179
-11,406,425
-1,818,715
Other income (expense), net
37,979
441,062
-117,539
-5,577
Interest expense
602,364
423,229
-107,578*
669,150
Interest income
45,741
46,673
98,602
100,698
Gain on equity investments, net
-
-11,252
12,374*
2,998
Gain on extinguishment of debt
-
-
17,152.5*
-
Gain on equity investments, net
3,650
-
-
-
Non-cash interest expense
401,413
390,350
175,938*
201,447
Change in fair value of derivative liability
577,347
231,968
2,460,354*
-311,778
Gain on digital assets
-
-
-
57
Unrealized loss on digital assets
-
-
-147,229*
-
Gain/(loss) on digital assets
-404,145
-442,439
-
-
Change in fair value of convertible notes
-2,384,374
239,480
-2,150,530.5*
-2,178,039
Foreign currency transaction, net
-33,336
-313,157
1,155,658*
-271,937
Total other income (expense), net
-3,160,915
-621,244
1,260,482
-3,534,175
Loss before income taxes
-6,086,522
-2,805,423
-10,145,943
-5,352,890
Income tax expense
0
0
0
0
Net loss
-
-
-
-5,352,890
Deemed dividend on issuance of warrants
-
-
0*
0
Deemed dividend on warrant exchange/modification
-
-
0*
0
Net loss
-6,086,522
-2,805,423
-10,145,943
-5,352,890
Net loss attributable to common stockholders
-
-2,805,423
-10,145,943
-
Foreign currency translation adjustment, net
-
-295,061
-382,567
255,263
Total comprehensive loss
-
-3,100,484
-10,528,510
-5,097,627
Basic EPS
-0.1
-0.06
-0.295
-0.17
Diluted EPS
-0.1
-0.06
-0.295
-0.17
Basic Average Shares
59,923,199
47,087,621
35,739,904
30,625,284
Diluted Average Shares
59,923,199
47,087,621
35,739,904
30,625,284
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net loss
-$6,086,522
(-115.22%↓ Y/Y)
Greece
$18,316,956
(28.60%↑ Y/Y)
Uk
$608,803
(121.90%↑ Y/Y)
Albania
$41,383
(109.31%↑ Y/Y)
Cyprus
$19,234
(-45.09%↓ Y/Y)
Loss before income
taxes
-$6,086,522
(-115.22%↓ Y/Y)
Revenue
$18,986,376
(28.76%↑ Y/Y)
Total other income
(expense), net
-$3,160,915
(-1629.65%↓ Y/Y)
Loss from operations
-$2,925,607
(-10.60%↓ Y/Y)
Change in fair value of
derivative liability
$577,347
Gross profit
$1,511,662
(29.89%↑ Y/Y)
Interest income
$45,741
(-56.76%↓ Y/Y)
Other income
(expense), net
$37,979
(190.02%↑ Y/Y)
Cost of goods sold
$17,474,714
(28.66%↑ Y/Y)
Gain on equity
investments, net
$3,650
(38.31%↑ Y/Y)
Change in fair value of
convertible notes
-$2,384,374
(-1608.10%↓ Y/Y)
Interest expense
$602,364
(54.92%↑ Y/Y)
Gain/(loss) on digital
assets
-$404,145
Total operating
expenses
$4,437,269
(16.49%↑ Y/Y)
Non-cash interest
expense
$401,413
(146.11%↑ Y/Y)
Foreign currency
transaction, net
-$33,336
(-107.53%↓ Y/Y)
General and
administrative expenses
$2,066,053
(38.62%↑ Y/Y)
Salaries and wages
$1,855,257
(-0.71%↓ Y/Y)
Depreciation and
amortization expense
$349,181
(-1.32%↓ Y/Y)
Sales and marketing
expenses
$98,226
(352.53%↑ Y/Y)
Research and development
costs
$68,552
(-8.15%↓ Y/Y)
Buy us a coffee
Cosmos Health Inc. (COSM)
Cosmos Health Inc. (COSM)